{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:02:01Z","timestamp":1793581321132,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol Exp"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We assessed the safety and efficacy of computed tomography (CT)-guided high-dose-rate (HDR) brachytherapy in treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From January 2010 to January 2022, 56 patients (median age 67.5 years) with HCC and PVTT underwent 64 procedures. PVTT was further classified according to the Japan liver cancer study group into VP1\u2013VP4. Tumor response was evaluated by cross-sectional imaging 6 weeks after CT-guided HDR brachytherapy and every 3 months thereafter. Local tumor control (LTC), progression-free survival (PFS), and overall survival (OS) were assessed using Kaplan\u2013Meier curves. The severity of procedure-related complications was classified according to the Society of Interventional Radiology guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Patients were available for imaging evaluation for a median follow-up of 14.0 months. The median diameter of the largest lesion was 56\u2009mm. Estimated median PFS, LTC, and OS were 7.0 (95% CI 5.0\u201313.0), 14.0 (95% CI 7.0\u201321.0), and 20.0 (95% CI 13.0\u201326.0) months respectively. Actuarial 1-, 2-, and 3-year OS rates were 66%, 41%, and 27%, respectively. Subclassified for VP1, VP2, VP3, and VP4 estimated OS was 38.0 (95% CI 9.0-Not-a-number), 21.5 (95% CI 15.0\u201325.0), 15.0 (95% CI 7.0\u201333.0), and 13.0 (95% CI 6.0\u201334.0) months, respectively. Considering the 64 procedures, we recorded no complications for 49 (76.6%), mild-to-moderate complications for 12 (18.8%), and major complications for 3 (4.7%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>CT-guided HDR brachytherapy was safe and effective for locoregional treatment in patients with advanced HCC due to PVTT, achieving long-lasting local tumor control.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Relevance statement<\/jats:title>\n            <jats:p>CT-guided HDR brachytherapy is an option to be considered for locoregional treatment of patients with advanced HCC due to PVTT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Points<\/jats:title>\n            <jats:p>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>Evaluation of CT-guided high-dose-rate (HDR) brachytherapy in treating HCC patients with portal vein tumor thrombosis (PVTT).<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>Median OS was 20.0 months ranging between 13.0 and 38.0 months.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>CT-guided HDR brachytherapy seems to be a safe and effective treatment option in HCC patients with PVTT.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s41747-025-00564-3","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T11:38:16Z","timestamp":1739533096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CT-guided high-dose-rate brachytherapy ablation of HCC patients with portal vein tumor thrombosis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5763-689X","authenticated-orcid":false,"given":"Timo Alexander","family":"Auer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Luise Helene Hildegard","family":"Ranner-Hafferl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Anhamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"B\u00f6ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli","family":"Fehrenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Geisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Kloeckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Collettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"564_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"564_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ejca.2009.12.018","volume":"46","author":"YH Kuo","year":"2010","unstructured":"Kuo YH, Lu SN, Chen CL et al (2010) Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 46:744\u2013751. https:\/\/doi.org\/10.1016\/j.ejca.2009.12.018","journal-title":"Eur J Cancer"},{"key":"564_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijsu.2015.05.009","volume":"20","author":"ZM Zhang","year":"2015","unstructured":"Zhang ZM, Lai EC, Zhang C et al (2015) The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg 20:8\u201316. https:\/\/doi.org\/10.1016\/j.ijsu.2015.05.009","journal-title":"Int J Surg"},{"key":"564_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1:EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070","journal-title":"NEJM Evid"},{"key":"564_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"564_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M et al (2022) Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76:862\u2013873. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030","journal-title":"J Hepatol"},{"key":"564_CR7","doi-asserted-by":"publisher","unstructured":"Zane KE, Makary MS (2021) Locoregional therapies for hepatocellular carcinoma with portal vein tumor thrombosis. Cancers (Basel) 13 https:\/\/doi.org\/10.3390\/cancers13215430","DOI":"10.3390\/cancers13215430"},{"key":"564_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11901-020-00559-1","volume":"20","author":"HR Thomas","year":"2021","unstructured":"Thomas HR, Feng M (2021) Stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma. Curr Hepatol Rep 20:12\u201322. https:\/\/doi.org\/10.1007\/s11901-020-00559-1","journal-title":"Curr Hepatol Rep"},{"key":"564_CR9","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.ijrobp.2003.09.024","volume":"58","author":"J Ricke","year":"2004","unstructured":"Ricke J, Wust P, Stohlmann A et al (2004) CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 58:1496\u20131505. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.09.024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"564_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00330-011-2352-7","volume":"22","author":"F Collettini","year":"2012","unstructured":"Collettini F, Schnapauff D, Poellinger A et al (2012) Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. Eur Radiol 22:1101\u20131109. https:\/\/doi.org\/10.1007\/s00330-011-2352-7","journal-title":"Eur Radiol"},{"key":"564_CR11","doi-asserted-by":"publisher","first-page":"e509","DOI":"10.1016\/j.ejrad.2013.04.046","volume":"82","author":"F Collettini","year":"2013","unstructured":"Collettini F, Singh A, Schnapauff D et al (2013) Computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of metastases adjacent to the liver hilum. Eur J Radiol 82:e509\u2013e514. https:\/\/doi.org\/10.1016\/j.ejrad.2013.04.046","journal-title":"Eur J Radiol"},{"key":"564_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108429","volume":"50","author":"TA Auer","year":"2024","unstructured":"Auer TA, Anhamm M, B\u00f6ning G et al (2024) Effectiveness and safety of computed tomography-guided high-dose-rate brachytherapy in treating recurrent hepatocellular carcinoma not amenable to repeated resection or radiofrequency ablation. Eur J Surg Oncol 50:108429. https:\/\/doi.org\/10.1016\/j.ejso.2024.108429","journal-title":"Eur J Surg Oncol"},{"key":"564_CR13","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.232044","volume":"310","author":"TA Auer","year":"2024","unstructured":"Auer TA, M\u00fcller L, Schulze D et al (2024) CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Radiology 310:e232044. https:\/\/doi.org\/10.1148\/radiol.232044","journal-title":"Radiology"},{"key":"564_CR14","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1200\/JCO.2022.40.16_suppl.4116","volume":"40","author":"A Saborowski","year":"2022","unstructured":"Saborowski A, Waldschmidt D, Hinrichs J et al (2022) IMMUTACE: a biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)\u2014Updated efficacy results. J Clin Oncol 40:4116\u20134116. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4116","journal-title":"J Clin Oncol"},{"key":"564_CR15","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s00270-021-02968-1","volume":"44","author":"P Lucatelli","year":"2021","unstructured":"Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T (2021) CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol 44:1851\u20131867. https:\/\/doi.org\/10.1007\/s00270-021-02968-1","journal-title":"Cardiovasc Intervent Radiol"},{"key":"564_CR16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jmri.28659","volume":"57","author":"R Patel","year":"2023","unstructured":"Patel R, Aslam A, Parikh ND et al (2023) Updates on LI-RADS treatment response criteria for hepatocellular carcinoma: focusing on MRI. J Magn Reson Imaging 57:1641\u20131654. https:\/\/doi.org\/10.1002\/jmri.28659","journal-title":"J Magn Reson Imaging"},{"key":"564_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-6-40","volume":"6","author":"M Seidensticker","year":"2011","unstructured":"Seidensticker M, Seidensticker R, Mohnike K et al (2011) Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiat Oncol 6:40. https:\/\/doi.org\/10.1186\/1748-717X-6-40","journal-title":"Radiat Oncol"},{"key":"564_CR18","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.jvir.2017.06.019","volume":"28","author":"O Khalilzadeh","year":"2017","unstructured":"Khalilzadeh O, Baerlocher MO, Shyn PB et al (2017) Proposal of a new adverse event classification by the Society of Interventional Radiology Standards of Practice Committee. J Vasc Interv Radiol 28:1432\u20131437.e1433. https:\/\/doi.org\/10.1016\/j.jvir.2017.06.019","journal-title":"J Vasc Interv Radiol"},{"key":"564_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1159\/000439101","volume":"33","author":"M Kudo","year":"2015","unstructured":"Kudo M, Kitano M, Sakurai T, Nishida N (2015) General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. Dig Dis 33:765\u2013770. https:\/\/doi.org\/10.1159\/000439101","journal-title":"Dig Dis"},{"key":"564_CR20","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/hep.29668","volume":"67","author":"EG Giannini","year":"2018","unstructured":"Giannini EG, Bucci L, Garuti F et al (2018) Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. Hepatology 67:1784\u20131796. https:\/\/doi.org\/10.1002\/hep.29668","journal-title":"Hepatology"},{"key":"564_CR21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/liv.13988","volume":"39","author":"A M\u00e4hringer-Kunz","year":"2019","unstructured":"M\u00e4hringer-Kunz A, Steinle V, D\u00fcber C et al (2019) Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: the more, the worse? Liver Int 39:324\u2013331. https:\/\/doi.org\/10.1111\/liv.13988","journal-title":"Liver Int"},{"key":"564_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver. Electronic address EEE","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address EEE (2018) EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 69:182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"key":"564_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/ajco.13361","volume":"17","author":"HS Choi","year":"2021","unstructured":"Choi HS, Kang KM, Jeong BK et al (2021) Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease. Asia Pac J Clin Oncol 17:209\u2013215. https:\/\/doi.org\/10.1111\/ajco.13361","journal-title":"Asia Pac J Clin Oncol"},{"key":"564_CR24","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold A, Massey CA, Kim JJ et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31:1631\u20131639. https:\/\/doi.org\/10.1200\/JCO.2012.44.1659","journal-title":"J Clin Oncol"},{"key":"564_CR25","doi-asserted-by":"publisher","unstructured":"Abouchaleh N, Gabr A, Ali R et al (2018) 90Y Radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med 59:1042\u20131048. https:\/\/doi.org\/10.2967\/jnumed.117.199752","DOI":"10.2967\/jnumed.117.199752"},{"key":"564_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B et al (2024) Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 Trial. J Nucl Med 65:264\u2013269. https:\/\/doi.org\/10.2967\/jnumed.123.266211","journal-title":"J Nucl Med"},{"key":"564_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01779-5","volume":"16","author":"P Wust","year":"2021","unstructured":"Wust P, Beck M, Dabrowski R et al (2021) Radiotherapeutic treatment options for oligotopic malignant liver lesions. Radiat Oncol 16:51. https:\/\/doi.org\/10.1186\/s13014-021-01779-5","journal-title":"Radiat Oncol"}],"container-title":["European Radiology Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-025-00564-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41747-025-00564-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-025-00564-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T23:09:23Z","timestamp":1739574563000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurradiolexp.springeropen.com\/articles\/10.1186\/s41747-025-00564-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1186\/s41747-025-00564-3","relation":{},"ISSN":["2509-9280"],"issn-type":[{"value":"2509-9280","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Retrospective study approved bay Charit\u00e9's Ethics Committee (EA1\/163\/22) which waived the patients\u2019 consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}